Monostotic fibrous dysplasia

Summary

Monostotic fibrous dysplasia (MONDO:0019665) is a disease. A subtype of fibrous dysplasia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	monostotic fibrous dysplasia
Mondo ID	MONDO:0019665
MeSH	D005358
Orphanet	93277
ICD-11	1033883899
NCIT	C53971
SNOMED CT	89859004
UMLS	C0016064
MedGen	42020
GARD	0019181
Is cancer (heuristic)	no

Also known as: Jaffe-Lichtenstein disease · monostotic fibrous dysplasia · monostotic fibrous dysplasia (disease) · monostotic fibrous dysplasia of bone

Data availability: 1 HPO phenotype.

Disease family

This is a subtype of fibrous dysplasia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › skeletal system disorder › bone disorder › bone remodeling disease › fibrous dysplasia › monostotic fibrous dysplasia

Related subtypes (2): polyostotic fibrous dysplasia, panostotic fibrous dysplasia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.